Study Sheds Light on Factors Contributing to Low-Level Viremia in HIV Patients

Human immunodeficiency virus (HIV) works by entering specific immune cells and replicating inside them. People with HIV are treated with antiretroviral therapy (ART), which prevents viral replication, but some individuals taking ART continue to have low levels of viral presence in the bloodstream, or viremia. This condition is usually attributed to drug resistance or ineffectiveness of ART, but recent studies have found that low-level viremia can occur even without these driving forces, a condition known as non-suppressible HIV viremia (NSV).

A team led by researchers at the Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, recruited eight participants with NSV despite receiving ART and analyzed both the virus and host immune response.

Using sequencing assays, the researchers found large reservoirs of proviruses -; viral genetic material that has been integrated into host DNA -; inserted into transcriptionally active regions of immune cell genomes. Although unable to replicate due to ART, these proviruses contained mutations that helped them evade detection and were able to express genes leading to the NSV phenotype. In addition, the investigators found that the study participants had altered gene expression patterns that led to dampened immune responses and increased survival of cells infected with HIV.

The authors also suggest that these mechanisms could contribute to low levels of residual viremia in most individuals with HIV, even if they successfully undergo ART.

Our study has identified potential mediators of non-suppressible viremia. Furthering our understanding of these mechanisms could help develop strategies to disrupt viral persistence in all patients living with HIV."

Jonathan Li, MD, of the Division of Infectious Diseases

Source:
Journal reference:

Mohammadi, A., et al. (2023). Viral and host mediators of non-suppressible HIV-1 viremia. Nature Medicine. doi.org/10.1038/s41591-023-02611-1.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Deciphering the Significance of m6A RNA Modification in HIV-1 Genome